News Lilly trumpets strong result for Jaypirca in CLL at EHA New data with Eli Lilly's Jaypirca at EHA 2026 has cemented its place as a second-line therapy for chronic lymphocytic leukaemia.
News Data could move J&J's Talvey earlier in myeloma therapy Johnson & Johnson's Talvey looks set to move second-line in multiple myeloma treatment, based on the results of the MonumenTAL-3 trial at EHA 2026.
News Incyte gobbles up Star's Vega haematology unit in $2bn deal Incyte has agreed to buy Star Therapeutics' Vega subsidiary for $1.25bn upfront, adding a late-stage drug candidate for bleeding disorder VWD.
News Roche doubles down on BTK with $2.3bn Nurix deal Roche is paying $700m upfront for rights to bexobrutideg, a BTK degrader that it says has potential across oncology, immunology, and neurology.
News AbbVie's Immunogen buy delivers rare cancer drug approval AbbVie's Decnupaz approval will give patients with rare blood cancer BPDCN an alternative to Stemline's Elzonris with a simpler dosing regimen.
News FDA hands BeOne, Taiho approvals for blood cancers BeOne gets the nod for BCL2 inhibitor Beqalzi in mantle cell lymphoma, while Taiho's Inqovi has acute myeloid leukaemia added to its label.
Oncology ASCO 2026: Can a blood test spot cancer early? with Dr Peter... Dr Peter Sasieni, co-investigator for the NHS Galleri trial, discusses advances in population-level blood screening for early cancer detection.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
